Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2005 2
2006 2
2007 4
2008 5
2009 2
2010 5
2011 2
2012 6
2013 4
2014 4
2015 7
2016 5
2017 7
2018 12
2019 10
2020 22
2021 9
2022 7
2023 8
2024 7

Text availability

Article attribute

Article type

Publication date

Search Results

112 results

Results by year

Filters applied: . Clear all
Page 1
Germ line predisposition variants occur in myelodysplastic syndrome patients of all ages.
Feurstein S, Trottier AM, Estrada-Merly N, Pozsgai M, McNeely K, Drazer MW, Ruhle B, Sadera K, Koppayi AL, Scott BL, Oran B, Nishihori T, Agrawal V, Saad A, Lindsley RC, Nakamura R, Kim S, Hu Z, Sobecks R, Spellman S, Saber W, Godley LA. Feurstein S, et al. Among authors: scott bl. Blood. 2022 Dec 15;140(24):2533-2548. doi: 10.1182/blood.2022015790. Blood. 2022. PMID: 35969835 Free PMC article.
Myeloablative Versus Reduced-Intensity Hematopoietic Cell Transplantation for Acute Myeloid Leukemia and Myelodysplastic Syndromes.
Scott BL, Pasquini MC, Logan BR, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick ED, Fernandez HF, Alyea EP, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Le-Rademacher J, Mendizabal AM, Horowitz MM, Deeg HJ, Horwitz ME. Scott BL, et al. J Clin Oncol. 2017 Apr 10;35(11):1154-1161. doi: 10.1200/JCO.2016.70.7091. Epub 2017 Feb 13. J Clin Oncol. 2017. PMID: 28380315 Free PMC article. Clinical Trial.
Impact of Conditioning Intensity of Allogeneic Transplantation for Acute Myeloid Leukemia With Genomic Evidence of Residual Disease.
Hourigan CS, Dillon LW, Gui G, Logan BR, Fei M, Ghannam J, Li Y, Licon A, Alyea EP, Bashey A, Deeg HJ, Devine SM, Fernandez HF, Giralt S, Hamadani M, Howard A, Maziarz RT, Porter DL, Scott BL, Warlick ED, Pasquini MC, Horwitz ME. Hourigan CS, et al. Among authors: scott bl. J Clin Oncol. 2020 Apr 20;38(12):1273-1283. doi: 10.1200/JCO.19.03011. Epub 2019 Dec 20. J Clin Oncol. 2020. PMID: 31860405 Free PMC article.
Myeloablative versus Reduced-Intensity Conditioning for Hematopoietic Cell Transplantation in Acute Myelogenous Leukemia and Myelodysplastic Syndromes-Long-Term Follow-Up of the BMT CTN 0901 Clinical Trial.
Scott BL, Pasquini MC, Fei M, Fraser R, Wu J, Devine SM, Porter DL, Maziarz RT, Warlick E, Fernandez HF, Soiffer RJ, Alyea E, Hamadani M, Bashey A, Giralt S, Geller NL, Leifer E, Hourigan CS, Gui G, Mendizabal A, Horowitz MM, Deeg HJ, Horwitz ME. Scott BL, et al. Transplant Cell Ther. 2021 Jun;27(6):483.e1-483.e6. doi: 10.1016/j.jtct.2021.02.031. Epub 2021 Feb 26. Transplant Cell Ther. 2021. PMID: 33775615 Free PMC article. Clinical Trial.
Indication and management of allogeneic haematopoietic stem-cell transplantation in myelofibrosis: updated recommendations by the EBMT/ELN International Working Group.
Kröger N, Bacigalupo A, Barbui T, Ditschkowski M, Gagelmann N, Griesshammer M, Gupta V, Hamad N, Harrison C, Hernandez-Boluda JC, Koschmieder S, Jain T, Mascarenhas J, Mesa R, Popat UR, Passamonti F, Polverelli N, Rambaldi A, Robin M, Salit RB, Schroeder T, Scott BL, Tamari R, Tefferi A, Vannucchi AM, McLornan DP, Barosi G. Kröger N, et al. Among authors: scott bl. Lancet Haematol. 2024 Jan;11(1):e62-e74. doi: 10.1016/S2352-3026(23)00305-8. Epub 2023 Dec 4. Lancet Haematol. 2024. PMID: 38061384 Review.
Myelodysplastic syndromes.
Scott BL, Deeg HJ. Scott BL, et al. Annu Rev Med. 2010;61:345-58. doi: 10.1146/annurev.med.051308.132852. Annu Rev Med. 2010. PMID: 20059342 Review.
BOREAS: a global, phase III study of the MDM2 inhibitor navtemadlin (KRT-232) in relapsed/refractory myelofibrosis.
Verstovsek S, Al-Ali HK, Mascarenhas J, Perkins A, Vannucchi AM, Mohan SR, Scott BL, Woszczyk D, Koschmieder S, García-Delgado R, László R, McGreivy JS, Rothbaum WP, Kiladjian JJ. Verstovsek S, et al. Among authors: scott bl. Future Oncol. 2022 Nov 23. doi: 10.2217/fon-2022-0901. Online ahead of print. Future Oncol. 2022. PMID: 36416118 Free article. Review.
Randomized, Single-Blind, Multicenter Phase II Study of Two Doses of Imetelstat in Relapsed or Refractory Myelofibrosis.
Mascarenhas J, Komrokji RS, Palandri F, Martino B, Niederwieser D, Reiter A, Scott BL, Baer MR, Hoffman R, Odenike O, Vannucchi AM, Bussolari J, Zhu E, Rose E, Sherman L, Dougherty S, Sun L, Huang F, Wan Y, Feller FM, Rizo A, Kiladjian JJ. Mascarenhas J, et al. Among authors: scott bl. J Clin Oncol. 2021 Sep 10;39(26):2881-2892. doi: 10.1200/JCO.20.02864. Epub 2021 Jun 17. J Clin Oncol. 2021. PMID: 34138638 Clinical Trial.
Transplantation for myelodysplastic syndromes 2013.
Vaughn JE, Scott BL, Deeg HJ. Vaughn JE, et al. Among authors: scott bl. Curr Opin Hematol. 2013 Nov;20(6):494-500. doi: 10.1097/MOH.0b013e328364f547. Curr Opin Hematol. 2013. PMID: 24104409 Free PMC article. Review.
112 results